Wilsons disease treatment market

Wilson’s Disease Treatment Market, by Treatment Medications (D-Penicillamine, Trientine, Zinc, Tetrathiomolybdate), Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Government bodies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Request Free Sample

Jun 2022
CMI526
185 Pages
Excel & Pdf
Pharmaceutical

Summary

Wilson's illness is inherited as an autosomal recessive trait, which means that patient must have inherited one copy of the defective gene from each parent in order to acquire the disease. Patient won't get unwell if patient only have one faulty gene, but he/she will be a carrier and can pass the gene on to their children. According to data published by National Library of Medicines, Wilson's disease symptoms usually appear between the ages of 12 and 23, and untreated patients can live for up to 40 years. Early detection and treatment of Wilson’s disease, on the other hand, may help people live longer. Copper isn't adequately eliminated in Wilson's illness, it accumulates in the body above normal levels. Between the ages of 12 and 23, symptoms of Wilson’s disease are Swelling, weariness, stomach pain, and uncontrolled or poorly coordinated motions are among symptoms.

Moreover, medications such as D-Penicillamine, Trientine that cause the organs, normally the liver releases extra copper into the bile, bile carries copper, waste products, toxins to digestive tract and excrete are frequently used in treatment. It can then be removed from the body through kidneys once it has entered the bloodstream. Wilson’s disease is caused by disruption or alterations (mutations) in the ATP7B gene, which is involved in the transfer of excess copper from the liver to the bile, where it is finally expelled from the body through the intestines.

Global Wilson’s disease treatment market is estimated to be valued at US$ 527.0 million in 2022 and is expected to exhibit a CAGR of 6.2 % during the forecast period (2022-2030).

Figure 1.Global Wilson’s Disease Treatment Market Share (%) in Terms of Value, by Region, 2022

Rapid advancements in technology allowing for early diagnosis of Wilson’s disease is driving growth of the Wilson’s disease treatment market

Increasing advancement in techniques used for diagnosis of Wilson’s disease and it’s treatment has expected to drive the market growth over the forecast period. For instance, according to an article published by Translational Gastroenterology and Hepatology Journal in April 2021, several advances in diagnosis and genetic testing have proved to be helpful in early diagnosis to prevent long term complications of Wilson’s disease. Individuals with Wilson’s disease can be diagnosed using the clinical findings of Kayser Fleischer (KF) rings, cirrhosis, neurological, or mental problems like anxiety and depression in various combinations. Identification and quantification of Wilson’s disease has become easier due to recent advancement made in evaluating KF rings. A sensitive method for detection of KF rings by a non-ophthalmologist had been introduced in the anterior segment optical coherence tomography. Use of magnetic resonance (MR) spectroscopy of tissues in the pediatric population has severed as potential method for detecting early neurological involvement in pediatric patients with Wilson’s disease. One new method that has been recently discussed as capable diagnostic tool for Wilson’s disease diagnosis is liquid chromatography multiple reaction monitoring mass spectrometry.

Wilson’s Disease Treatment Market Report Coverage

Report Coverage	Details
Base Year:	2021	Market Size in 2022:	US$ 527.0 Mn
Historical Data for:	2017 to 2020	Forecast Period:	2022 to 2030
Forecast Period 2022 to 2030 CAGR:	6.2%	2030 Value Projection:	US$ 854.5 Mn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC Countries, Israel, and Rest of Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Treatment: Medications, D-Penicillamine, Trientine, Zinc, Tetrathiomolybdate, others By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Government Distribution Channel
Companies covered:	Valeant Pharmaceuticals International, Inc., Noblepharma Co., Ltd., Wilson Therapeutics AB, Kadmon Holdings, Inc., Merck & Co., Inc., VHB Life Science Ltd., Teva Pharmaceuticals USA, Inc., and Tsumura & Co.
Growth Drivers:	Rapid advancements in technology allowing for early diagnosis for Wilson’s disease Increase in awareness regarding Wilson’s disease
Restraints & Challenges:	Lack of awareness of Wilson’s disease Lack of diagnosis facilities for Wilson’s disease

Figure 2.Global Wilson’s Disease Treatment Market Share (%), by Distribution Channel, 2022

Increase in awareness regarding Wilson’s disease is expected to fuel the Wilson’s disease treatment market growth in near future

Various organizations are increasing awareness regarding Wilson’s disease, which is expected to drive market growth over the forecast period. Wilson’s disease association, associated in New York, U.S., is a volunteer organization striving to promote the well-being of patients with Wilson’s disease where they offer the latest information about the disease and its symptoms and treatment. Moreover Wilson’s disease association supports research and clinical investigation for Wilson’s disease.

Global Wilson’s Disease Treatment Market– Impact of Coronavirus (COVID-19) Pandemic

The coronavirus or COVID-19 outbreak was started in Wuhan, China in 2019 and spread across all the continents of the world, affecting various industries globally. The economies of countries all over the world, such as India, Italy, Bangladesh, Sri Lanka, the U.S., Morocco, and others, have been disrupted due to lockdowns implemented by governments to combat the spread of coronavirus since 2020.

The COVID-19 pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses across all sectors. The private healthcare sector is one such sector that has been majorly impacted by the pandemic. Furthermore, the negative effect of the COVID-19 outbreak on health care services and mental health has been and will continue to be notable because of the uncertainty and unpredictability of the pandemic, the associated physical distancing lockdowns, and other containment strategies, and the resulted in economic breakdown.

Recent Development in Wilson’s disease Treatment Market:

For instance, according to data published by AstraZeneca websites, in August 2021 the FoCus Phase III trial in Wilson disease had reported positive high-level results in showing that ALXN1840 met the primary endpoint with a statistically notable advancement in daily mean copper mobilization from tissues, demonstrating superiority compared with standard-of-care (SoC) treatments. ALXN1840, oral medicine, had demonstrated three times more copper mobilization than SoC. FoCus is a crucial, Phase III, rater-blinded randomized, multi-center clinical trial manufactured to evaluate the safety and efficacy of ALXN1840 versus SoC in patients with Wilson disease aged 12 years and older. ALXN1840 has been awarded Orphan Drug Designation in the US and EU for Wilson disease treatment.

Global Wilson’s disease Treatment Market: Restraint

The major factors that hinder growth of the global Wilson’s disease treatment market include lack of awareness and diagnosis facilities associated with Wilson’s disease treatment. For instance, according to data published by National Center for Biotechnology Information (NCBI) in April 2019, Wilson’s disease is rare autosomal recessive disorder and has stated that no single examination can unequivocally confirm or exclude the disease. Diagnosis of patients with Wilson’s disease is challenging as it is based on a complex set of clinical findings that are derived from physical examination, patient history as well as imaging testing and pathology laboratory with adequate facilities. The lack of all the mentioned facilities had made it difficult to collect the data and estimate about the diagnosis data about patients suffering with Wilson’s disease.

Key Players

Major players operating in the global Wilson’s disease treatment market include Valeant Pharmaceuticals International, Inc., Noblepharma Co., Ltd., Wilson Therapeutics AB, Kadmon Holdings, Inc., Merck & Co., Inc., VHB Life Science Ltd., Teva Pharmaceuticals USA, Inc., and Tsumura & Co.

Table of Content

Table of Contents

*Browse 25 market data tables and 29 figures on "Global Wilson’s Disease Treatment Market” - forecast to 2030

Segmentation

Detailed Segmentation:

- Frequently Asked Questions -

What is the current market size and compound annual growth rate (CAGR) of the global Wilson’s disease treatment market during the forecast period (2022-2030)?

Global Wilson’s disease treatment market size is estimated to be valued at US$ 527.0 million in 2022 and is expected to exhibit a CAGR of 6.2% between 2022 and 2030.

What are the major factors driving the market growth?

Factors such as rapid advancements in technology allowing for early diagnosis of Wilson’s Disease and increase in awareness regarding Wilson’s disease are expected to drive growth of the market during the forecast period.

Which is the leading type segment in the market?

Generics segment is the leading type segment in the market.

What are the key factors hampering growth of the market?

The key factors hampering growth of the market include lack of awareness and diagnosis facilities of Wilson’s disease.

Which are the major players operating in the market?

Major players operating in the market include Valeant Pharmaceuticals International, Inc., Noblepharma Co., Ltd., Wilson Therapeutics AB, Kadmon Holdings, Inc., Merck & Co., Inc., VHB Life Science Ltd., Teva Pharmaceuticals USA, Inc., and Tsumura & Co.